Loading data for CCCC — first visit, this takes a few seconds.

アラート

C4 Therapeutics Inc. (CCCC)

NasdaqGS: CCCC · リアルタイム株価 · USD

4.21

+0.03 (0.72%)

終値時点： Aug 19, 2026, 7:38 PM

0.72% (1D)

データがありません

買気配	n/a
時価総額	518.55M
売上高（TTM）	35.04M
純利益（TTM）	-101.42M
ベータ	2.95
EPS（TTM）	-0.91
PER（TTM）	n/a
予想PER	-4.23
PBR（TTM）	2.09
PSR（TTM）	14.80
Earnings Date	Nov 5, 2026

売気配	n/a
出来高	2,089,859
平均出来高（20日）	3,062,358
始値	4.25
前日終値	4.18
当日レンジ	4.13 - 4.38
52週レンジ	1.69 - 5.17
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

CCCCについて

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, ...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Oct 2, 2020

従業員数 104

上場取引所 NasdaqGS

ティッカー CCCC

ウェブサイト https://www.c4therapeutics.com

企業情報の全文

業績

2025年のC4 Therapeuticsの売上高は35.95Mで、前年の35.58Mから1.02%の増加でした。利益は-104.99Mで、-0.31%の減少でした。

財務諸表

決算サプライズ

C4 TherapeuticsはAug 11, 2026に四半期決算を発表しました：

売上高は $6.15M で、予想を下回りました $0, うち -15.00% の前年比減少.

EPSは -0.18 で、予想を上回りました 0.05, うち 51.35% の前年比増加にあたります.

次回決算発表

C4 Therapeutics Inc.の決算発表予定日は Nov 5, 2026, 寄り付き前の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1週間前 · Zacks

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +21.74% and +10.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1か月前 · Zacks

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.

1か月前 · Zacks

C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.

1か月前 · Insider Monkey

C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?

C4 Therapeutics, Inc. (NASDAQ:CCCC) has gained roughly 16% over the past month, mainly driven by positive phase 1 clinical trial data for Cemsidomide. The data was presented on June 11, following whic...

2か月前 · Zacks

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.

2ページ中1ページ

C4 Therapeutics Inc. (CCCC)